A β-sheet-binding scaffold was equipped with long-range chemical groups for tertiary contacts toward specific regions of the Alzheimer's Aβ fibril. The new constructs contain a trimeric aminopyrazole carboxylic acid, elongated with a C-terminal binding site, whose influence on the aggregation behavior of the Aβ(42) peptide was studied. MD simulations after trimer docking to the anchor point (F19/F20) suggest distinct groups of complex structures each of which featured additional specific interactions with characteristic Aβ regions. Members of each group also displayed a characteristic pattern in their antiaggregational behavior toward Aβ. Specifically, remote lipophilic moieties such as a dodecyl, cyclohexyl, or LPFFD fragment can form disp...
International audienceHow anti-Alzheimer’s drug candidates that reduce amyloid 1–42 peptide fibrilli...
A key pathogenic agent in Alzheimer's disease (AD) is the amyloid β-protein (Aβ), which self-assembl...
International audienceHow anti-Alzheimer’s drug candidates that reduce amyloid 1–42 peptide fibrilli...
Increasing evidence implicates Aβ peptides self-assembly and fibril formation as crucial events in t...
Several lines of evidence suggest that a characteristic of the neuropathology of Alzheimer's disease...
Increasing evidence implicates Aβ peptides self-assembly and fibril formation as crucial events in t...
A new series of mimetic peptides possessing a significant Aβ aggregation modulating effect was repor...
Amyloid fibrils associated with Alzheimer's disease and a wide range of other neurodegenerative dise...
A new series of mimetic peptides possessing a significant Aβ aggregation modulating effect was repor...
AbstractDeposition of amyloid fibrils, consisting primarily of Aβ40 and Aβ42 peptides, in the extrac...
A key pathogenic agent in Alzheimer's disease (AD) is the amyloid β-protein (Aβ), which self-assembl...
A key pathogenic agent in Alzheimer's disease (AD) is the amyloid β-protein (Aβ), which self-assembl...
A new concept is introduced for the rational design of β-sheet ligands, which prevent protein aggreg...
International audienceThe extracellular deposition of insoluble amyloid fibrils resulting from the a...
Drug design studies targeting one of the primary toxic agents in Alzheimer’s disease, soluble oligom...
International audienceHow anti-Alzheimer’s drug candidates that reduce amyloid 1–42 peptide fibrilli...
A key pathogenic agent in Alzheimer's disease (AD) is the amyloid β-protein (Aβ), which self-assembl...
International audienceHow anti-Alzheimer’s drug candidates that reduce amyloid 1–42 peptide fibrilli...
Increasing evidence implicates Aβ peptides self-assembly and fibril formation as crucial events in t...
Several lines of evidence suggest that a characteristic of the neuropathology of Alzheimer's disease...
Increasing evidence implicates Aβ peptides self-assembly and fibril formation as crucial events in t...
A new series of mimetic peptides possessing a significant Aβ aggregation modulating effect was repor...
Amyloid fibrils associated with Alzheimer's disease and a wide range of other neurodegenerative dise...
A new series of mimetic peptides possessing a significant Aβ aggregation modulating effect was repor...
AbstractDeposition of amyloid fibrils, consisting primarily of Aβ40 and Aβ42 peptides, in the extrac...
A key pathogenic agent in Alzheimer's disease (AD) is the amyloid β-protein (Aβ), which self-assembl...
A key pathogenic agent in Alzheimer's disease (AD) is the amyloid β-protein (Aβ), which self-assembl...
A new concept is introduced for the rational design of β-sheet ligands, which prevent protein aggreg...
International audienceThe extracellular deposition of insoluble amyloid fibrils resulting from the a...
Drug design studies targeting one of the primary toxic agents in Alzheimer’s disease, soluble oligom...
International audienceHow anti-Alzheimer’s drug candidates that reduce amyloid 1–42 peptide fibrilli...
A key pathogenic agent in Alzheimer's disease (AD) is the amyloid β-protein (Aβ), which self-assembl...
International audienceHow anti-Alzheimer’s drug candidates that reduce amyloid 1–42 peptide fibrilli...